Related Experiment Video
Updated: May 8, 2026
Iridium(III) Luminescent Probe for Detection of the Malarial Protein Biomarker Histidine Rich Protein-II
Published on: July 7, 2015
Mapping the protein-binding sites for novel iridium(III) anticancer complexes using electron capture dissociation
Rationale:
Application of Fourier transform ion cyclotron (FT-ICR) tandem mass spectrometry reveals the binding sites for novel cyclopentadienyl Ir(III) anticancer complexes on calmodulin. The conventional fragmentation methods, collisionally activated dissociation (CAD) and infrared multiphoton dissociation (IRMPD), failed to define the Ir modification, but these binding sites were located via electron capture dissociation (ECD).
Methods:
A combination of top-down and bottom-up methods was used to generate detailed information about the reaction of these compounds with a common signalling protein, calmodulin.
Results:
The research shows that such Ir-based complexes preferentially bind to methionine sites in the protein, and interestingly, the very low efficiency of the Ir modification is different compared to reactions of Pt(II) complexes, which can lead to protein crosslinking.
Conclusions:
This is the first report on reactions of novel Ir-based anticancer complexes with proteins, which provides helpful information for studying the protein targets of this category of metallodrug and the transportation mechanisms which allow them to inhibit cancer cell growth.
Insights
Novel iridium (Ir) anticancer complexes bind to specific methionine sites on calmodulin, identified using electron capture dissociation (ECD) mass spectrometry. This differs from platinum (Pt) complexes and aids understanding of metallodrug mechanisms.
Area of Science:
- Biochemistry
- Mass Spectrometry
- Medicinal Chemistry
Background:
- Novel cyclopentadienyl iridium(III) complexes show promise as anticancer agents.
- Understanding their interaction with biological targets like calmodulin is crucial for drug development.
- Conventional mass spectrometry fragmentation methods (CAD, IRMPD) were insufficient to pinpoint iridium binding sites.
Purpose of the Study:
- To identify the specific binding sites of novel Ir(III) anticancer complexes on the calmodulin protein.
- To investigate the reaction mechanisms of these iridium complexes with calmodulin.
- To compare the binding and modification patterns with established platinum(II) anticancer drugs.
Main Methods:
- Utilized Fourier transform ion cyclotron (FT-ICR) tandem mass spectrometry.
- Employed a combination of top-down and bottom-up mass spectrometry approaches.
- Electron capture dissociation (ECD) was key for localizing iridium modifications on calmodulin.
Main Results:
- Ir(III) complexes preferentially bind to methionine residues within calmodulin.
- The efficiency of iridium modification on the protein is notably low compared to platinum complexes.
- Unlike platinum(II) complexes, iridium complexes did not induce protein crosslinking.
Conclusions:
- This study provides the first report on the interaction of novel Ir-based anticancer complexes with proteins.
- The findings offer valuable insights into the protein targets of this class of metallodrugs.
- Understanding these interactions aids in elucidating mechanisms of cancer cell growth inhibition and drug transport.
